Manufacturing roundup: Aurisco completes FDA inspection of ingredient production site; NIH picks Exothera to develop nasal Covid vaccine
Aurisco Pharmaceutical said Tuesday that the FDA gave it the green light to produce active pharmaceutical ingredients (APIs) at a manufacturing site in Yangzhou, China.
The facility now has cGMP status and will produce several generic APIs, including semaglutide, Novo Nordisk’s blockbuster type 2 diabetes and obesity drug, according to a news release.
The FDA conducted the inspection between Aug. 7 and 11. No observations were found that warranted an inspection report.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.